<img width="364" height="150" src="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png" class="attachment-large size-large" alt="Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies" loading="lazy" decoding="async" srcset="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png 364w, https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header-300x124.png 300w" sizes="(max-width: 364px) 100vw, 364px" />

<img width="364" height="150" src="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png" class="attachment-large size-large" alt="Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies" loading="lazy" decoding="async" srcset="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png 364w, https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header-300x124.png 300w" sizes="(max-width: 364px) 100vw, 364px" />

Miltenyi Cell & Gene Therapy

Korecyte Bio’s CSO, Dr Arnold, presented HypoxiCAR technology at the Miltenyi Biotec Cell and Gene Therapy Days. The preclinical data were shared that support the potential of HypoxiCAR technology for the field of CAR-T therapy against solid tumours. Held at Miltenyi Biotec in Bergisch Gladbach, Germany (October 18-19, 2023).